ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "DMARDs"

  • Abstract Number: 1488 • 2014 ACR/ARHP Annual Meeting

    Clinical Efficacy of Add-on Iguratimod Therapy in Patients with Active Rheumatoid Arthritis Despite of Methotrexate ~a Multicenter Registry Study~

    Yasuhide Kanayama1, Toshihisa Kojima2, Atsushi Kaneko3, Yuji Hirano4, Nobunori Takahashi2, Shinya Hirabara4 and Naoki Ishiguro2, 1Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan, 2Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 3Orthopedic Surgery and Rheumatology, Nagoya Medical Center, Nagoya, Japan, 4Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan

    Background/Purpose  Iguratimod (IGU) is a small-molecule antirheumatic drug that was approved in Japan in September 2012. IGU suppressed tumor necrosis factor-alpha-induced production of interleukin (IL)-6,…
  • Abstract Number: 423 • 2014 ACR/ARHP Annual Meeting

    Circulating Anti-Citrullinated Peptide Antibodies and Cytokines As Biomarkers of Response to Disease-Modifying Antirheumatic Drugs Therapy in Early Rheumatoid Arthritis

    Mahmood MTM Ally1, Pieter Meyer2, Bridget Hodkinson3, Eustasius Musenge4, Gregory Tintinger2, Mohammed Tikly5 and Ronald Anderson1, 1University of Pretoria, Pretoria, South Africa, 2university of pretoria, pretoria, South Africa, 3Rheumatology, University of the Witwatersrand, Johannesburg, South Africa, 4University of Witwatersrand, Johannesburg, South Africa, 5Rheumatology Wits University, C H Baragwanath Hospital, Johannesburg, South Africa

    Background/Purpose Serial measurement of circulating anti-citrullinated peptide antibodies (ACPA) and cytokines is of potential importance in the management of patients with rheumatoid arthritis (RA). However,…
  • Abstract Number: 2810 • 2014 ACR/ARHP Annual Meeting

    Reduced Mortality Risk in Rheumatoid Arthritis: Findings from Two UK Inception Cohorts

    Sam Norton1, Elena Nikiphorou2, Lewis Carpenter3, David Walsh4,5, Patrick Kiely6, Josh Dixey7 and Adam Young2,8, 1Institute of Psychiatry, King's College London, London, United Kingdom, 2School of Life & Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom, 3Centre for Lifespan & Chronic Illness Research, University of Hertfordshire, Hatfield, United Kingdom, 4Arthritis Research UK Pain Centre, University of Nottingham, Nottingham, United Kingdom, 5Rheumatology, Sherwood Forest Hospitals NHS Foundation Trust, Sutton-in-Ashfield, United Kingdom, 6Rheumatology Dept, St. Georges Healthcare NHS Trust, London, United Kingdom, 7Rheumatology, New Cross Hospital, Wolverhampton, United Kingdom, 8Rheumatology, ERAS, St Albans City Hospital, St Albans, United Kingdom

    Background/Purpose Rheumatoid arthritis (RA) is associated with a 20 to 30% increased risk of mortality from all-causes compared to the general population. The aim of…
  • Abstract Number: 1497 • 2014 ACR/ARHP Annual Meeting

    Efficacy and Safety of Iguratimod for Rheumatoid Arthritis

    Tsuneo Kondo1, Akiko Shibata1, Ryota Sakai1, Kentaro Chino1, Ayumi Okuyama1, Hirofumi Takei1 and Koichi Amano2, 1Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan, 2Saitama Medical Center, Saitama Medical University, Kawagoe, Japan

    Background/Purpose: Iguratimod is a new small-molecular drug for rheumatoid arthritis (RA), which was approved on June, 2012 in Japan. The agent inhibits the production of…
  • Abstract Number: 301 • 2014 ACR/ARHP Annual Meeting

    Pregnancies in Females with Juvenile Idiopathic Arthritis (JIA) Who Were Exposed to Biologics and/or Methotrexate – Results from a Biologic Register

    Katrin Stüdemann1, Martina Niewerth1, Jens Klotsche1, Angela Zink2, Gerd Horneff3 and Kirsten Minden1,4, 1Epidemiology unit, German Rheumatism Research Center, Berlin, Germany, 2German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, 3Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, 4Chidlrens´ hospital, Charité University Medicine, Berlin, Germany

    Background/Purpose JIA often continues into adult life and affects about 1 in 1,000 people of childbearing age. Little is known about the impact of JIA…
  • Abstract Number: 2555 • 2014 ACR/ARHP Annual Meeting

    The Effect of Co-Medication with Conventional Synthetic (cs)Dmards on Achieving Low Disease Activity While Persisting on Adalimumab Therapy in Patients with Ankylosing Spondylitis/ Axial Spondylarthritis (AS)– Analysis from the Czech Biologics Registry Attra

    Karel Pavelka1, Jakub Zavada2, Marketa Fojtikova3, Sarka Forejtova4 and Karel Hejduk5, 1Institute of Rheumatology, Prague, Czech Republic, 2Charles University, Prague, Czech Republic, 3Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 4Rheumatology, Institute of Rheumatology, Prague, Czech Republic, 5Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic

    Background/Purpose : The role of combined treatment with csDMARDs and anti-TNF therapy in AS is not well established. Methods: Main goal of this study was…
  • Abstract Number: 1489 • 2014 ACR/ARHP Annual Meeting

    Influences of Disease Activity at the Initiation of Iguratimod, a Small Molecule Antirheumatic Drug, on Efficacy of Iguratimod in Patients with Rheumatoid Arthritis –a Multicenter Registry Study-

    Yuji Hirano1, Toshihisa Kojima2, Yasuhide Kanayama3, Shinya Hirabara1, Nobunori Takahashi2, Atsushi Kaneko4 and Naoki Ishiguro2, 1Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, 2Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 3Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan, 4Orthopedic Surgery and Rheumatology, Nagoya Medical Center, Nagoya, Japan

    Background/Purpose: Iguratimod (IGU), known as T-614, is a small-molecule antirheumatic drug developed in Japan and used in Japanese clinical practice since June in 2012. IGU…
  • Abstract Number: 274 • 2014 ACR/ARHP Annual Meeting

    Treatment Prescribing Patterns in a Cohort of Patients with Juvenile Idiopathic Arthritis (JIA). Data from the Childhood Arthritis Prospective Study

    Rebecca Davies1, Roberto Carrasco2, Helen Foster3, Eileen Baildam4, Alice Chieng5, Joyce Davidson6, Yiannis Ioannou7, Lucy R. Wedderburn8, Wendy Thomson9, Kimme L. Hyrich10 and on Behalf Of Childhood Arthritis Prospective Study (CAPS)11, 1Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, 2Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, 3Newcastle University, Newcastle, United Kingdom, 4Paediatric Rheumatology, Alder Hey Children's Foundation NHS Trust, Liverpool, United Kingdom, 5Manchester Children's Hospital, Manchester, United Kingdom, 6Royal Hospital for Sick Children, Glasgow, United Kingdom, 7Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, 8Rheumatology Unit, Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom, 9Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, 10Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, 11university of Manchester, Manchester, United Kingdom

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is a heterogenous disease, classified according to the International League of Associations for Rheumatology (ILAR). Initial treatment is based largely…
  • Abstract Number: 2565 • 2014 ACR/ARHP Annual Meeting

    The Effect of DMARD Co-Therapy on the Clinical Efficacy of Anti-TNF Medications in Patients with Axial Spondyloarthritis

    Michael J. Nissen1, Adrian Ciurea2, Juerg Bernhard3, Rudiger Muller4, Giorgio Tamborrini5, Martin Toniolo6, Cem Gabay7 and Axel Finckh1, 1Rheumatology, Geneva University Hospital, Geneva, Switzerland, 2Gloriastrasse 25, Rheumaklinik, Universitatsspital Zurich, Zurich, Switzerland, 3Rheumatology, Solothurn Hospital, Solothurn, Switzerland, 4Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, 5Department of Rheumatology and Musculoskeletal Ultrasound, Bethesda Hospital Basel, Basel, Switzerland, 6Department of Rheumatology, University Hospital of Zurich, Zurich, Switzerland, 7University Hospitals of Geneva/SCQM Registry, Geneva, Switzerland, Geneva, Switzerland

    Background/Purpose: Randomized clinical trials and current recommendations suggest little role for disease-modifying anti-rheumatic drugs (DMARDs) as co-therapy with anti-TNF (aTNF) agents in patients with axial-spondyloarthritis…
  • Abstract Number: 1452 • 2014 ACR/ARHP Annual Meeting

    Timing of Decisions to Adjust Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy for Rheumatoid Arthritis (RA) Patients with Active Disease in a Usual Practice Setting

    Yomei Shaw1, Chung-Chou H. Chang2, Marc C. Levesque3, Julie M. Donohue4, Kaleb Michaud5,6 and Mark S. Roberts1, 1Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, 2Department of Medicine, University of Pittsburgh Department of Medicine, Pittsburgh, PA, 3Division of Rheumatology and Clinical Immunology, University of Pittsburgh Department of Medicine, Pittsburgh, PA, 4Health Policy & Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, 5National Data Bank for Rheumatic Diseases, Wichita, KS, 6Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Current guidelines recommend that rheumatoid arthritis (RA) patients with poor response to their current regimen of disease modifying anti-rheumatic drugs (DMARDs) have therapy adjusted…
  • Abstract Number: L2 • 2014 ACR/ARHP Annual Meeting

    A Comparison of Three Treatment Strategies in Recent Onset DMARD Naïve Juvenile Idiopathic Arthritis: 3-Months Results of the BeSt for Kids-Study

    Petra C.E. Hissink Muller1,2, D.M.C. Brinkman1,3, Dieneke Schonenberg4, Yvonne Koopman-Keemink5, J. Merlijn Van den Berg6, W.P. Bekkering7, Marion van Rossum8,9, Lisette WA van Suijlekom-Smit10, Cornelia F. Allaart11 and Rebecca ten Cate1, 1Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Pediatric Rheumatology, Reade, Amsterdam, Netherlands, 3Pediatric Rheumatology, Rijnland Hospital, Leiderdorp, Netherlands, 4Department of Pediatric Rheumatology and Immunology, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands, 5Pediatrics, Haga ziekenhuis, The Hague, Netherlands, 6Pediatric Hematology, Immunology and Infectious diseases, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands, 7Pediatric Physiotherapy, Leiden University Medical Center, Leiden, Netherlands, 8Pediatric Rheumatology Immunology, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands, 9Reade, Amsterdam, Netherlands, 10Pediatric Rheumatology, Sophia Children's Hospital Erasmus Medical Center, Rotterdam, Netherlands, 11Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: BeSt for Kids compares 3 Disease Modifying Anti Rheumatic Drug (DMARD) strategies in juvenile idiopathic arthritis (JIA) patients, for time to inactive disease, time…
  • Abstract Number: 1760 • 2013 ACR/ARHP Annual Meeting

    Relationships Between Driving Distance, Rheumatoid Arthritis Diagnosis, and Disease-Modifying Anti-Rheumatic Drug Receipt

    Jennifer M. Polinski1, M. Alan Brookhart2, John Z. Ayanian3, Jeffrey N. Katz4, Seo Young Kim5, Chris Tonner6, Edward H. Yelin7 and Daniel H. Solomon8,9, 1Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, 2University of North Carolina, Chapel Hill, NC, 3Brigham and Women's Hospital, Boston, MA, 4Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA, 5Division of Rheumatology; Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA, 6Medicine, University of California, San Francisco, San Francisco, CA, 7Arthritis Research Group, University of California, San Francisco, San Francisco, CA, 8Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, 9Division of Rheumatology, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Disease-modifying antirheumatic drugs (DMARDs) are recommended for all patients with rheumatoid arthritis (RA). Some studies estimate that almost half of patients with RA do…
  • Abstract Number: 441 • 2013 ACR/ARHP Annual Meeting

    Tofacitinib, An Oral Janus Kinase Inhibitor: Safety Comparison In Patients With Rheumatoid Arthritis and An Inadequate Response To Nonbiologic Or Biologic Disease‑Modifying Anti-Rheumatic Drugs

    G. R. Burmester1, C Charles-Schoeman2, J. D. Isaacs3, T. Hendrikx4, K. Kwok5, S. H. Zwillich6 and R. Riese6, 1Department of Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Centre Berlin (DRFZ), Charité University Medicine Berlin, Berlin, Germany, 2University of California, Los Angeles, CA, 3Newcastle University, Newcastle-upon-Tyne, United Kingdom, 4Pfizer BV, Capelle aan den IJssel, Netherlands, 5Pfizer Inc, New York, NY, 6Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This analysis provides comparative safety data on the incidence…
  • Abstract Number: 1713 • 2013 ACR/ARHP Annual Meeting

    Disparity In Biologic Therapy In Ethnic Minorities With Rheumatoid Arthritis: Can It All Be Due To Lack Of Access To Drug?

    Gail S. Kerr1, Ted R. Mikuls2, Christopher J. Swearingen3, Chunqiao Luo4 and Yusuf Yazici5, 1Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, 2Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 3Pediatric Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, 4Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, 5Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY

    Background/Purpose: Ethnic disparities in the administration of DMARDs exist, but the impact of differing health care systems on access in ethnic minorities treated by rheumatologists,…
  • Abstract Number: 442 • 2013 ACR/ARHP Annual Meeting

    Tolerability and Non-Serious Adverse Events In Rheumatoid Arthritis Patients Treated With Tofacitinib As Monotherapy Or In Combination Therapy

    A. Dikranian1, K. Soma2, R. Riese2, D. Gruben2 and T. V. Jones3, 1San Diego Arthritis Medical Clinic, San Diego, CA, 2Pfizer Inc, Groton, CT, 3Pfizer Inc, Collegeville, PA

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Tolerability remains an ill-defined construct in clinical trials.…
  • « Previous Page
  • 1
  • …
  • 16
  • 17
  • 18
  • 19
  • 20
  • …
  • 24
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology